Related Experiment Video
Updated: Mar 3, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2
John C Pickup1, Yves Reznik2, Alex J Sutton3
1Division of Diabetes & Nutritional Sciences, King's College London, and Guy's Hospital, London, U.K. john.pickup@kcl.ac.uk.
Diabetes Care
|April 22, 2017
Summary
Continuous subcutaneous insulin infusion (CSII) offers better glycemic control than multiple daily injections (MDI) for type 2 diabetes patients with poor control. CSII significantly reduces insulin needs by approximately 26% without affecting weight.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Diabetes Management
Background:
- Type 2 diabetes (T2D) management often involves insulin therapy.
- Continuous subcutaneous insulin infusion (CSII) and multiple daily insulin injections (MDI) are primary insulin delivery methods.
- Comparing the efficacy and patient characteristics for optimal treatment selection is crucial.
Purpose of the Study:
- To compare glycemic control between CSII and MDI in T2D patients.
- To identify patient characteristics that predict better outcomes with CSII.
Main Methods:
- Meta-analysis of randomized controlled trials comparing CSII and MDI in T2D.
- Bayesian meta-regression used to analyze patient-level determinants of glycemic control (HbA1c) and insulin dose.
- Two-step meta-analysis for summary effects.
Main Results:
- Five trials involving 590 patients (287 MDI, 303 CSII) were analyzed.
- Baseline HbA1c was the strongest predictor of final HbA1c, with greater improvement in those with higher baseline levels.
- CSII resulted in a 0.40% lower HbA1c and a 26% reduction in daily insulin dose compared to MDI, with no significant weight change.
Conclusions:
- CSII provides superior glycemic control compared to MDI in T2D patients with poor baseline control.
- Patients with higher baseline HbA1c and insulin doses benefit most from CSII.
- CSII offers a significant reduction in insulin requirements for selected T2D patients.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
959
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
959
01:27Insulin Formulations: Types and Delivery
875
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
875
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
317
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
317
01:22Diabetes Mellitus: Overview and Type I Subtype
5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
01:06Oral Hypoglycemic Agents: Glinides
760
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
760